questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Mécanismes moléculaires de l'action pharmacologique
Antienzymes
Inhibiteurs de prolyle hydroxylases
Inhibiteurs de prolyle hydroxylases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Quantitative Structure-Activity Relationship
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de prolyle hydroxylases : Questions médicales les plus fréquentes",
"headline": "Inhibiteurs de prolyle hydroxylases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteurs de prolyle hydroxylases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-14",
"dateModified": "2025-05-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de prolyle hydroxylases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antienzymes",
"url": "https://questionsmedicales.fr/mesh/D004791",
"about": {
"@type": "MedicalCondition",
"name": "Antienzymes",
"code": {
"@type": "MedicalCode",
"code": "D004791",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de prolyle hydroxylases",
"alternateName": "Prolyl-Hydroxylase Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D064800",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Christopher J Schofield",
"url": "https://questionsmedicales.fr/author/Christopher%20J%20Schofield",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry , University of Oxford , Chemistry Research Laboratory , 12 Mansfield Road , Oxford , OX1 3TA , UK . Email: christopher.schofield@chem.ox.ac.uk."
}
},
{
"@type": "Person",
"name": "Anthony Tumber",
"url": "https://questionsmedicales.fr/author/Anthony%20Tumber",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry , University of Oxford , Chemistry Research Laboratory , 12 Mansfield Road , Oxford , OX1 3TA , UK . Email: christopher.schofield@chem.ox.ac.uk."
}
},
{
"@type": "Person",
"name": "Tetsuhiro Tanaka",
"url": "https://questionsmedicales.fr/author/Tetsuhiro%20Tanaka",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology and Endocrinology, The University of Tokyo School of Medicine."
}
},
{
"@type": "Person",
"name": "Masaomi Nangaku",
"url": "https://questionsmedicales.fr/author/Masaomi%20Nangaku",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology and Endocrinology, The University of Tokyo School of Medicine."
}
},
{
"@type": "Person",
"name": "Martine I Abboud",
"url": "https://questionsmedicales.fr/author/Martine%20I%20Abboud",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Oxford, Oxford, OX1 3TA, UK."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Design, Synthesis, Antibacterial Evaluation, Three-Dimensional Quantitative Structure-Activity Relationship, and Mechanism of Novel Quinazolinone Derivatives.",
"datePublished": "2023-02-21",
"url": "https://questionsmedicales.fr/article/36807581",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.jafc.2c07264"
}
},
{
"@type": "ScholarlyArticle",
"name": "Automated machine learning approach for developing a quantitative structure-activity relationship model for cardiac steroid inhibition of Na",
"datePublished": "2023-06-24",
"url": "https://questionsmedicales.fr/article/37354314",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s43440-023-00508-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Multivariate image analysis applied to quantitative structure-activity relationships and docking studies of recent hydroxyphenylpyruvate deoxygenase inhibitors.",
"datePublished": "2023-04-18",
"url": "https://questionsmedicales.fr/article/37021557",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jsfa.12608"
}
},
{
"@type": "ScholarlyArticle",
"name": "Artificial Intelligence-Based Quantitative Structure-Property Relationship Model for Predicting Human Intestinal Absorption of Compounds with Serotonergic Activity.",
"datePublished": "2023-04-18",
"url": "https://questionsmedicales.fr/article/37070956",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.molpharmaceut.2c01117"
}
},
{
"@type": "ScholarlyArticle",
"name": "Development of a quantitative structure-activity relationship model for predicting quantum yield of hydroxyl radical generation from organic compounds.",
"datePublished": "2023-01-25",
"url": "https://questionsmedicales.fr/article/36504232",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1039/d2em00396a"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antienzymes",
"item": "https://questionsmedicales.fr/mesh/D004791"
},
{
"@type": "ListItem",
"position": 6,
"name": "Inhibiteurs de prolyle hydroxylases",
"item": "https://questionsmedicales.fr/mesh/D064800"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteurs de prolyle hydroxylases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de prolyle hydroxylases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteurs de prolyle hydroxylases",
"description": "Comment diagnostiquer une carence en oxygène ?\nQuels tests sont utilisés pour évaluer l'efficacité des inhibiteurs ?\nQuels symptômes indiquent un besoin d'inhibiteurs ?\nComment évaluer l'anémie liée à l'hypoxie ?\nQuels marqueurs biologiques sont pertinents ?",
"url": "https://questionsmedicales.fr/mesh/D064800?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteurs de prolyle hydroxylases",
"description": "Quels sont les symptômes d'une hypoxie ?\nComment se manifeste l'anémie ?\nQuels signes indiquent une amélioration avec les inhibiteurs ?\nLes inhibiteurs affectent-ils l'appétit ?\nQuels symptômes peuvent aggraver l'état ?",
"url": "https://questionsmedicales.fr/mesh/D064800?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteurs de prolyle hydroxylases",
"description": "Comment prévenir l'hypoxie chez les patients à risque ?\nQuels modes de vie favorisent une bonne oxygénation ?\nLes vaccinations aident-elles à prévenir l'hypoxie ?\nComment éviter les complications liées à l'anémie ?\nLes contrôles réguliers sont-ils nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D064800?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteurs de prolyle hydroxylases",
"description": "Comment fonctionnent les inhibiteurs de prolyle hydroxylases ?\nQuels sont les effets secondaires des inhibiteurs ?\nLes inhibiteurs sont-ils utilisés en monothérapie ?\nQuelle est la durée du traitement avec ces inhibiteurs ?\nY a-t-il des alternatives aux inhibiteurs ?",
"url": "https://questionsmedicales.fr/mesh/D064800?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteurs de prolyle hydroxylases",
"description": "Quelles complications peuvent survenir avec l'hypoxie ?\nLes inhibiteurs peuvent-ils causer des complications ?\nComment gérer les complications liées à l'anémie ?\nQuels sont les risques d'une surdose d'inhibiteurs ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D064800?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteurs de prolyle hydroxylases",
"description": "Quels facteurs augmentent le risque d'hypoxie ?\nL'âge influence-t-il le risque d'anémie ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe mode de vie affecte-t-il le risque d'hypoxie ?\nLes conditions environnementales influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D064800?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une carence en oxygène ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des examens d'imagerie peuvent évaluer l'oxygénation."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité des inhibiteurs ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de fonction pulmonaire et des dosages d'érythropoïétine sont courants."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un besoin d'inhibiteurs ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, essoufflement et pâleur peuvent signaler une hypoxie nécessitant un traitement."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'anémie liée à l'hypoxie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un hémogramme et des tests de fer aident à diagnostiquer l'anémie."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont pertinents ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux d'érythropoïétine et d'hémoglobine sont des marqueurs clés."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une hypoxie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, confusion, essoufflement et cyanose."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'anémie ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'anémie se manifeste par fatigue, pâleur, et parfois des palpitations."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une amélioration avec les inhibiteurs ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une augmentation de l'énergie et une réduction de l'essoufflement sont des signes d'amélioration."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs affectent-ils l'appétit ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains patients peuvent ressentir une amélioration de l'appétit avec un meilleur oxygénation."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent aggraver l'état ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'augmentation de la fatigue et des douleurs thoraciques peuvent aggraver l'état."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hypoxie chez les patients à risque ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveiller régulièrement la fonction pulmonaire et traiter les maladies sous-jacentes."
}
},
{
"@type": "Question",
"name": "Quels modes de vie favorisent une bonne oxygénation ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée, l'exercice régulier et l'arrêt du tabac favorisent l'oxygénation."
}
},
{
"@type": "Question",
"name": "Les vaccinations aident-elles à prévenir l'hypoxie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations contre les infections respiratoires peuvent réduire le risque d'hypoxie."
}
},
{
"@type": "Question",
"name": "Comment éviter les complications liées à l'anémie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et un traitement précoce de l'anémie sont essentiels."
}
},
{
"@type": "Question",
"name": "Les contrôles réguliers sont-ils nécessaires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des contrôles réguliers permettent de détecter précocement les problèmes d'oxygénation."
}
},
{
"@type": "Question",
"name": "Comment fonctionnent les inhibiteurs de prolyle hydroxylases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils bloquent l'enzyme prolyle hydroxylase, augmentant ainsi la production d'érythropoïétine."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des inhibiteurs ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des nausées, des vertiges et des maux de tête."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs sont-ils utilisés en monothérapie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être utilisés seuls ou en association avec d'autres traitements selon le cas."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement avec ces inhibiteurs ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée dépend de la réponse au traitement et de la gravité de l'hypoxie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des alternatives aux inhibiteurs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des transfusions sanguines et des suppléments de fer peuvent être des alternatives."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'hypoxie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des lésions organiques, des troubles cognitifs et des arythmies."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs peuvent-ils causer des complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme l'hypertension et des troubles gastro-intestinaux peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'anémie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement approprié et un suivi régulier sont essentiels pour gérer les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'une surdose d'inhibiteurs ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surdose peut entraîner des effets indésirables graves, nécessitant une attention médicale."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié et rapide."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'hypoxie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les maladies pulmonaires, le tabagisme et l'obésité augmentent le risque d'hypoxie."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'anémie ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées sont plus susceptibles de développer une anémie."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux d'anémie ou de maladies respiratoires augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque d'hypoxie ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sédentaire et une mauvaise alimentation augmentent le risque d'hypoxie."
}
},
{
"@type": "Question",
"name": "Les conditions environnementales influencent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, vivre en altitude ou dans des zones polluées peut augmenter le risque d'hypoxie."
}
}
]
}
]
}
Plant bacterial illnesses are common and cause dramatic damage to agricultural goods all over the world, yet there are few efficient bactericides to alleviate them at present. To discover novel antiba...
Quantitative structure-activity relationship (QSAR) modeling is a method of characterizing the relationship between chemical structures and biological activity. Automated machine learning enables comp...
The chemical structures and inhibitory activities of 215 CS derivatives were obtained from the scientific literature. Predictive QSAR models were constructed using molecular descriptors, fingerprints,...
The best predictive QSAR models were selected based on the LogLoss value. Using these models, the Matthews correlation coefficient, F1 score, and area under the curve of the test dataset were 0.6729, ...
The automated machine learning-based QSAR method developed here should be applicable for the time-efficient construction of predictive models using only a small number of compounds....
Mesotrione is a triketone widely used as an inhibitor of the hydroxyphenylpyruvate deoxygenase (HPPD) enzyme. However, new agrochemicals should be developed continuously to tackle the problem of herbi...
The MIA-QSAR models based on van der Waals radii (r...
Multivariate image analysis descriptors corroborated by docking studies were capable of modeling the herbicidal activities of 68 triketones reliably. Due to the substituent effects at the triketone fr...
Oral medicines represent the largest pharmaceutical market area. To achieve a therapeutic effect, a drug must penetrate the intestinal walls, the main absorption site for orally delivered active pharm...
Organic compounds are capable of generating hydroxyl radicals (˙OH) through their excited triplet states in natural water. It is of significance to reveal the underlying mechanism of the generation an...
Fungal genera Alternaria and Fusarium include human and plant pathogenic species. Several antifungals have been used for their control, but excessive use has contributed to resistance development in p...
To evaluate in vitro and in silico the antifungal activities of terpenoids against Alternaria alternata and Fusarium oxysporum....
The minimum inhibitory concentration and minimum fungicidal concentration values of 27 constituents of essential oils used against Alternaria alternata and Fusarium oxysporum were evaluated in vitro. ...
The evaluated compounds proved to be effective antifungals. Thymol was the most active with a minimum inhibitory concentration of 91.6 ± 28.8 μg/ml for A. alternata and F. oxysporum. Quantitative stru...
Terpenoids exhibit relevant antifungal activities that should be incorporated into the study of medicinal chemistry. Inclusion of in silico assays in the in vitro evaluation is a valuable tool in the ...
Currently, increasing availability and popularity of designer benzodiazepines (DBZDs) constitutes a primary threat to public health. To assess this threat, the biological activity/potency of DBZDs was...
3D-QSAR models were established by collecting 46 multivariate-substituted 4-oxyquinazoline HDAC6 inhibitors. The relationship of molecular structure and inhibitory activity was studied by comparative ...
The leading cause of atherosclerotic cardiovascular disease (ASCVD) is elevated low-density lipoprotein cholesterol (LDL-C). Proprotein convertase subtilisin/kexin type 9 (PCSK9) attaches to the domai...
A positron emission tomography (PET) radioligand for imaging phosphodiesterase 4D (PDE4D) would benefit drug discovery and the investigation of neuropsychiatric disorders. The most promising radioliga...